The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Sunday, September 14, 2025

3:00 PM ET Doors open

3:30–5:00 PM ET Presentation

Baltimore Marriott Waterfront | Fourth Floor, Essex A-C

cecCONCEPTS
HEALTHCARE EDUCATION

The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Activity Description

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

Target Audience

Neurologists, neuro-oncologists, neurosurgeons, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

This program is supported through an independent educational grant from SpringWorks Therapeutics, Inc.

Faculty

Angela Hirbe
MD, PhD (Moderator)

Miriam Bornhorst
MD

Carlos Romo
MD

Renie Moss
Patient Advocate and Caregiver

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Assess neuro-oncologic features of neurofibromatosis type 1, including tumor types and neurological signs, to support early recognition and inform clinical decision-making
- Evaluate the use of MEK inhibitors in the management of neurofibromatosis type 1–associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events
- Develop evidence-based, interprofessional care plans for pediatric and adult patients with neurofibromatosis type 1 that reflect current clinical standards and support individualized, longitudinal management

The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Accreditation

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center

This activity is designated for 1.50 contact hours.

Oncology Nursing Certification (ONCC) [ILNA]

This activity is designated for 1.5 contact hours. The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Physician Assistants (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Faculty

Angela Hirbe
MD, PhD (Moderator)

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, MI

Angela Hirbe, MD, PhD, is a practicing medical oncologist who treats sarcoma. Her research focuses on utilization of genomic information from sarcomas to better understand the pathogenesis of these tumors and to identify biomarkers and therapeutic targets for these aggressive cancers.

Miriam Bornhorst
MD

Associate Professor
Max Lacewell Endowed Brain Tumor Research Scholar
Ann & Robert H. Lurie Children's Hospital of Chicago
Northwestern University Feinberg School of Medicine
Chicago, IL

Miriam Bornhorst, MD, is a pediatric neuro-oncologist at Lurie Children's Hospital (LCH), a principal investigator at the Stanley Manne Children's Research institute, Max Lacewell Endowed Brain Tumor Research Scholar, and Associate Professor in Pediatrics at Northwestern University, Chicago, Illinois. Her research interest and experience are in the discovery of tumor biomarkers that predict tumor behavior, including response to treatment. She has an active funded research project looking at baseline metabolism in neurofibromatosis type 1 (NF1) and how to leverage changes in metabolism to prevent/treat plexiform neurofibromas. Dr. Bornhorst also has an active project researching SV patterns within tumors associated with risk for progression/decreased treatment response and is investigating novel drug combinations for brain tumors. In her role as a neuro-oncologist, she has extensive experience with the clinical care of children with brain tumors, NF1, and cancer predisposition, including clinical trial development and execution.

The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Faculty

Carlos Romo

MD

Assistant Professor of Neurology, Oncology and Medicine
Director of Clinical Research, Neurofibromatosis Therapeutic Acceleration Program
Johns Hopkins University School of Medicine
Baltimore, MD

Carlos Romo, MD, is Assistant Professor of Neurology, Oncology and Medicine at The Johns Hopkins University School of Medicine, Attending Physician at the Johns Hopkins Comprehensive Neurofibromatosis Center, and Director of Clinical Research of the Neurofibromatosis Therapeutic Acceleration Program. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences. He then completed a Neuro-oncology clinical and research fellowship in a joint program between Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at Johns Hopkins University and completed training on clinical cancer research at The University of Texas MD Anderson Cancer Center. His research interests include early-phase clinical trials for the treatment of neurofibromatosis and gliomas.

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Patient Advocate

Renie Moss

Patient Advocate and Caregiver

Renie Moss lives in Vestavia Hills, AL, with her husband of 24 years, Philip Sr., and two children, Philip Jr. (age 20) and Helen (age 17). Philip Jr. was diagnosed with neurofibromatosis type 1 in 2011 when a tumor was discovered in his neck. Following her son's diagnosis, Helen and Philip Sr. were both diagnosed in 2013. Renie is an avid advocate for the neurofibromatosis community and the scientific and medical leaders dedicated to finding effective treatments for neurofibromatosis. She is a former chair of the Children's Tumor Foundation (CTF) Volunteer Leadership Council and served as patient liaison to the Synodos NF1 Research Consortium. She is also a patient representative for Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration (REiNS), helping researchers develop standardized response criteria for determining treatment responses in neurofibromatosis. Local to Alabama, Renie provides patient and caregiver perspectives by serving on the University of Alabama at Birmingham (UAB) NF Clinic Patient Advisory Board and the UAB Genetic Counseling Program's Advisory Board. She assists in coordinating the annual UAB NF Symposium and Family Day, connecting with newly diagnosed patients and their families to provide support and encouragement. Professionally, Renie serves as the Operations Administrator for the Gregory Fleming James Cystic Fibrosis Research Center at the University of Alabama at Birmingham. She holds an undergraduate degree in English and master's degrees in education and public health from University of Alabama at Birmingham.

The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Disclosure Declarations

It is the policy of Creative Educational Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. Creative Educational Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Hirbe reports the following financial relationships:

Advisory Board: Aadi Subsidiary, Inc.

Consultant: Aadi Subsidiary, Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; and SpringWorks Therapeutics, Inc.

Grants: Tango

Other financial or material support: Boehringer Ingelheim

Dr. Bornhorst reports the following financial relationships:

Consultant: Alexion Pharmaceuticals, Inc.

Dr. Romo reports the following financial relationships:

Advisory Board: SpringWorks Therapeutics, Inc.

Consultant: Alexion Pharmaceuticals, Inc.

Patient Advocate/Planner

Renie Moss–no disclosures to report.

Peer Reviewers

Alaa Bawaneh, MD, PhD–no disclosures to report.

Andrea Edwards, PA-C–no disclosures to report.

CEC Staff/Planners

Susan Perry–no disclosures to report.

Nichole Lainhart–no disclosures to report.

David Modrak, PhD–no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP–no disclosures to report.

Sandra Caballero, PharmD–no disclosures to report.

Sharon Tordoff–no disclosures to report.

**All identified conflicts of interest have been mitigated.*

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

The MEKtrix

Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty.

Ask Faculty a Question

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

View and Take Notes on Presentation Slides

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to log in to or to create a learner account.

Downloadable Resources

Downloadable resources will be available at **ceconcepts.com/MEKTRIXresources**.

Engage with Us

Follow us **@ceconcepts** for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

ceCONCEPTS HEALTHCARE EDUCATION